Development of the antiparkinsonian drug with novel mechanism by drug-reprofiling.
| Project/Area Number |
25460204
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Multi-year Fund |
|---|
| Section | 一般 |
|---|
| Research Field |
Medical pharmacy
|
|---|
| Research Institution | Asahikawa Medical College |
|---|
Principal Investigator |
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
FUKUDO Masahide 旭川医科大学, 医学部, 准教授 (60437233)
Kamiyama Naoya 旭川医科大学, 医学部, 助教 (20431398)
|
|---|
| Project Period (FY) |
2013-04-01 – 2016-03-31
|
| Project Status |
Completed (Fiscal Year 2015)
|
| Budget Amount *help |
¥4,940,000 (Direct Cost: ¥3,800,000、Indirect Cost: ¥1,140,000)
Fiscal Year 2015: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Fiscal Year 2014: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
Fiscal Year 2013: ¥2,080,000 (Direct Cost: ¥1,600,000、Indirect Cost: ¥480,000)
|
|---|
| Keywords | パーキンソン病治療薬 / オキシカム系非ステロイド性抗炎症薬 / メロキシカム / 新規進行抑制薬 / 神経細胞死抑制 / パーキンソン病進行抑制薬 / オキシカム系NSAIDs / meloxicam / ドラッグリプロファイリング / Akt / 細胞生存シグナル / 神経細胞死抑制薬 / オキシカム系NSAIDｓ / TrkA / mTOR |
|---|
| Outline of Final Research Achievements |
Non-steroidal anti-inflammatory Drugs (NSAIDs) with oxicam structure have been reported to show neuroprotection via a novel mechanism which is to maintain cell-survival Akt signal in our research. Meloxicam, one of the oxicams, showed neuroprotection in a parkinsonian animal model. However, other oxicams had been investigated regarding antiparkinsonian effects. We examined other oxicams in the animal model. No drugｓ except meloxicam show neuroprotection. We obtained some new findings in relation to the mechanism of meloxicam for neuroprotection. Meloxicam is expected as a novel antiparkinsonian drug with disease-modifying effect.
|
Report
(4 results)
Research Products
(2 results)
